TD Cowen analyst Yaron Werber raised the firm’s price target on Ascendis Pharma (ASND) to $227 from $194 and keeps a Buy rating on the shares. The firm said they posted a strong Q2 Yorvipath beat but a Skytrofa miss due to foreign exchange headwinds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma price target raised to $230 from $210 at RBC Capital
- Ascendis Pharma price target raised to $307 from $306 at UBS
- Ascendis Pharma price target raised to $290 from $243 at Citi
- Ascendis Pharma price target raised to $295 from $289 at Wells Fargo
- Ascendis Pharma’s Promising Growth Trajectory: Buy Rating Affirmed Amid Strong Yorvipath Performance and Strategic Pipeline Developments